--- title: "Neurogene (NGNE) news: offering" url: "https://aibio.space/companies/neurogene/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NGNE offering news: Neurogene agrees to $200.0 million private placement at $50.00 per share. Neurogene Inc. (NASDAQ: NGNE), United States." --- NGNE Neurogene Inc. NASDAQ · United States # Neurogene (NGNE) news NGNE offering news Distress · 2024-11-14 ## [Neurogene delays quarterly report for period ended September 30, 2024](https://aibio.space/news/neurogene-delays-quarterly-report-period-ended-september-30-2024/) The company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days. ## Latest Neurogene news 1. 2024-11-04 Financings [Neurogene agrees to $200.0 million private placement at $50.00 per share](https://aibio.space/news/neurogene-agrees-200-0-million-private-placement-50-00-share/) Neurogene is selling 1,835,000 shares and pre-funded warrants for up to 2,165,042 shares to a group of healthcare investors. ## Neurogene at a glance - **Ticker**: NGNE - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $225.4 million ### Related companies - [Vaccinex](https://aibio.space/companies/vaccinex/) OTC: VCNX - [Abpro Holdings](https://aibio.space/companies/abpro/) OTC: ABPO - [Inhibrx Biosciences](https://aibio.space/companies/inhibrx-biosciences/) NASDAQ: INBX - [Korsana Biosciences](https://aibio.space/companies/korsana-biosciences/) NASDAQ: KRSA - [Ensysce Biosciences](https://aibio.space/companies/ensysce-biosciences/) NASDAQ: ENSC - [Gain Therapeutics](https://aibio.space/companies/gain-therapeutics/) NASDAQ: GANX - [Aridis Pharmaceuticals](https://aibio.space/companies/aridis-pharmaceuticals/) OTC: ARDS - [Arcus Biosciences](https://aibio.space/companies/arcus-biosciences/) NYSE: RCUS ### Also on NASDAQ - [Cryoport](https://aibio.space/companies/cryoport/) CYRX - [Intercure](https://aibio.space/companies/intercure/) INCR - [Adaptive Biotechnologies](https://aibio.space/companies/adaptive-biotechnologies/) ADPT - [BIOMERICA INC](https://aibio.space/companies/biomerica/) BMRA - [Tenaya Therapeutics](https://aibio.space/companies/tenaya-therapeutics/) TNYA - [Cellectar Biosciences](https://aibio.space/companies/cellectar-biosciences/) CLRB ## Neurogene annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/) | [$925,000](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/) | | Research and development | [$75.0 million](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/) | [$60.9 million](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/) | | Net income (loss) | [-$90.4 million](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/) | [-$75.1 million](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/) | | Cash from operations | [-$77.2 million](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/) | [-$70.6 million](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/) | | Cash and equivalents | [$103.8 million](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000059/) | [$136.6 million](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/) | | Short-term investments | [$165.2 million](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000059/) | [$175.8 million](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $112.5 million, plus short-term investments of $112.9 million, $225.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Neurogene Has Neurogene raised money recently? Our latest story on this, dated Nov 4, 2024: "Neurogene agrees to $200.0 million private placement at $50.00 per share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/neurogene-agrees-200-0-million-private-placement-50-00-share/). What is the ticker symbol of Neurogene? Neurogene Inc. trades under the ticker NGNE on NASDAQ. Where is Neurogene listed? Neurogene Inc. is listed on NASDAQ. Our directory also records these other listings: LS:A3EX79; LSX:A3EX79. What is the SEC CIK of Neurogene? The SEC Central Index Key (CIK) for Neurogene Inc. is 1404644. Its filings are on SEC EDGAR. How many shares does Neurogene have outstanding? 20,011,382 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Neurogene listed under? Our directory records Neurogene Inc. under United States. What does Neurogene do? Our directory classifies Neurogene Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Neurogene? The ISIN recorded for Neurogene Inc. is US64135M1053. Does aibio.space cover Neurogene? aibio.space lists Neurogene Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What was Neurogene's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Neurogene profitable? Neurogene Inc. reported a net loss of $90.4 million for the fiscal year ended Dec 31, 2025, and used $77.2 million of cash in operations, per its annual report to the SEC. How much does Neurogene spend on research and development? $75.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Neurogene have? $225.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Neurogene (NGNE) stock news? Our latest story on Neurogene, dated Nov 14, 2024: "Neurogene delays quarterly report for period ended September 30, 2024". The company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days. [Source](https://aibio.space/news/neurogene-delays-quarterly-report-period-ended-september-30-2024/). Is Neurogene in financial distress? Our latest distress story, dated Nov 14, 2024: "Neurogene delays quarterly report for period ended September 30, 2024". The company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days. [Source](https://aibio.space/news/neurogene-delays-quarterly-report-period-ended-september-30-2024/). ## Investor discussion: Neurogene Members talk about Neurogene (NGNE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Neurogene, newest first. Each line links the filing it comes from. 1. 2026-06-30 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1404644/000162828026046237/ngne-june2026cmpoxprelimin.htm) 2. 2025-08-11 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1404644/000162828025039623/ngne-2025atmprospectussupp.htm) 3. 2025-03-24 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1404644/000162828025014521/neurogene-sx3shelf.htm) 4. 2024-12-02 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1404644/000162828024049615/ngne-20241202.htm) 5. 2024-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1404644/000140464424000094/ngne-form12bx25q32024form1.htm) 6. 2024-11-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1404644/000140464424000089/ngne-20241104.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NGNE on TradingView](https://www.tradingview.com/symbols/NASDAQ-NGNE/). ## SEC filings and registration - **SEC name**: Neurogene Inc. - **CIK**: 1404644 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NGNE (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 535 W 24TH STREET, NEW YORK, NY, 10011 - **Phone**: (877) 237-5020 - **Shares outstanding**: 20,011,382 as of 2026-08-07 (10-Q filed 2026-08-11) - **Former names**: Neoleukin Therapeutics, Inc.; AQUINOX PHARMACEUTICALS, INC; AQUINOX PHARMACEUTICALS (USA) INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000059/ngne-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000056/ngne-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000050/ngne-20260630.htm) filed 2026-07-02 - [424B5](https://www.sec.gov/Archives/edgar/data/1404644/000162828026046666/ngne-june2026cmpoxfinalpro.htm) filed 2026-07-02 - [424B5](https://www.sec.gov/Archives/edgar/data/1404644/000162828026046237/ngne-june2026cmpoxprelimin.htm) filed 2026-06-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000046/ngne-20260629.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000044/ngne-20260608.htm) filed 2026-06-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000040/ngne-20260603.htm) filed 2026-06-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001404644), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Neurogene Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NGNE, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Neurogene Inc. - **Ticker**: NGNE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US64135M1053 - **Other listed symbols**: LS:A3EX79; LSX:A3EX79 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NGNE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/neurogene/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Neurogene (NGNE) news: offering", 2026-10-31, https://aibio.space/companies/neurogene/